Astria Therapeutics, Inc. (ATXS)

Market Cap	336.91M
Revenue (ttm)	n/a
Net Income (ttm)	-108.04M
Shares Out	56.43M
EPS (ttm)	-1.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198,157
Open	6.16
Previous Close	6.24
Day's Range	5.96 - 6.16
52-Week Range	3.56 - 12.92
Beta	0.41
Analysts	Strong Buy
Price Target	32.43 (+444.13%)
Earnings Date	Aug 11, 2025

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder assoc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS
• Website: https://www.astriatx.com

Analyst Summary

According to 7 analysts, the average rating for ATXS stock is "Strong Buy." The 12-month stock price target is $32.43, which is an increase of 444.13% from the latest price.

Price Target

$32.43

(444.13% upside)

Analyst Consensus: Strong Buy